| Updated biotechnological approaches developed for 2,7'-cyclolignan production1. | |
| | |
MedLine Citation:
|
PMID: 20222870 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
2,7'-Cyclolignans constitute a group of compounds regularly employed in clinical contexts due to their antiviral and anticancer properties as expressed in a number of already available designed drugs. Possibilities for other therapeutic developments are indicated. All commercial preparations actually originate from a single compound, podophyllotoxin, currently extracted from a few limited-in-abundance species of Podophyllum. This supply problem has stimulated considerable interest in the development of alternative strategies offering greater sustainable availability of the compound at affordable costs. Approaches such as plant breeding and micropropagation of the high-producing Podophyllum species have been explored with the aim of establishing production of these compounds. Since 20 years of exploration of the total chemical synthesis of podophyllotoxin has not proved economically viable, extensive research has now been undertaken to find methods for stimulating the accumulation of 2,7'-cyclolignans using tissue cultures. Both undifferentiated and differentiated cell cultures, mainly from Linum, Podophyllum, Juniperus, Callitris, Anthriscus and Forsynthia genera, have been reported. Although considerable progress has been made concerning the concentration and productivity of certain strains of Linum album, no economically viable production system has been established. Exploration and development of biosynthetical pathways leading to 2,7'-cyclolignans may open paths for future metabolic engineering, such as the bioconversion of deoxypodophyllotoxin to epipodophyllotoxin employing a human hepatic enzyme heterologously expressed in Escherichia coli. |
| | |
Authors:
|
Emmanuelle Lautié; Marc-André Fliniaux; Maria Luisa Villarreal |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-03-12 |
Journal Detail:
|
Title: Biotechnology and applied biochemistry Volume: 55 ISSN: 1470-8744 ISO Abbreviation: Biotechnol. Appl. Biochem. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-03-12 Completed Date: 2010-06-21 Revised Date: 2010-09-01 |
Medline Journal Info:
|
Nlm Unique ID: 8609465 Medline TA: Biotechnol Appl Biochem Country: England |
Other Details:
|
Languages: eng Pagination: 139-53 Citation Subset: IM |
Affiliation:
|
Faculté de Pharmacie, Université de Picardie Jules Verne, Unité de Recherche EA3900-BioPI, 1 rue des Louvels, F80037 Amiens, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Bioreactors Biotechnology* Lignans / biosynthesis* Plants / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Lignans |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: TNF-alpha reduces the activity of the Na+/K+ ATPase in LLC-PK1 by activating caspases and JNK and in...
Next Document: Silk-based materials for biomedical applications.